Background: Patients with acute lymphocytic leukemia (ALL) often experience relapse of their disease following standard treatment. Blinatumomab (Blincyto®) is a newly approved option for inducing remission in individuals with relapsed or refractory Philadelphia chromosome–negative B-cell ALL...

Purpose/Objectives: To assess fear of progression (FoP) in outpatients with chronic myeloid leukemia (CML) on oral tyrosine kinase inhibitors (TKIs). Design: Prospective and descriptive. Setting: A university-based outpatient cancer clinic in Wuerzburg, Germany. Sample: 37 outpatients with CML on...

Purpose/Objectives: To review common tyrosine kinase inhibitors, as well as their ocular side effects and management. Data Sources: A comprehensive literature search was conducted using CINAHL®, PubMed, and Cochrane databases for articles published since 2004 with the following search terms: ocular...

Background: The development of targeted therapies has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), with new clinical trials and therapies consistently providing new information. This rapidly changing field mandates ongoing education for nursing professionals whose...